2026-08-13 · retatrutide, LY3437943, triple agonist, GLP-1, GIP, glucagon, TRIUMPH, Eli Lilly, obesity pharmacology, investigational drugs

What is retatrutide and who makes it?

Retatrutide (development code LY3437943) is an investigational once-weekly subcutaneous injection developed by Eli Lilly. It is a single peptide that activates three receptors at once — GLP-1, GIP, and glucagon — which is why it is called a triple agonist or tri-agonist. The GLP-1 and GIP arms produce the appetite suppression and improved insulin sensitivity familiar from tirzepatide (Zepbound / Mounjaro); the glucagon arm adds an energy-expenditure and hepatic-fat-mobilization lever that no currently approved obesity drug provides. It is still in Phase 3 development and is not FDA-approved for any indication as of publication.

How is retatrutide different from Ozempic and Zepbound?

Ozempic and Wegovy (semaglutide) target one receptor (GLP-1). Zepbound and Mounjaro (tirzepatide) target two (GLP-1 and GIP). Retatrutide targets three (GLP-1, GIP, and glucagon). The additional glucagon receptor activation is the mechanistic novelty — it can raise resting energy expenditure and mobilize liver fat, which the two-receptor and one-receptor drugs do not do. In the Jastreboff 2023 NEJM Phase 2 trial, retatrutide at 12 mg weekly produced roughly 24.2 percent mean weight loss at 48 weeks, versus tirzepatide's roughly 20.9 percent at 72 weeks in SURMOUNT-1 (Jastreboff 2022 NEJM) and semaglutide's roughly 14.9 percent in STEP-1 (Wilding 2021 NEJM). No head-to-head trial exists yet.

How much weight can retatrutide help you lose?

The best published data are from the Jastreboff 2023 NEJM Phase 2 trial. At the 12 mg weekly dose, mean weight change at 48 weeks was roughly minus 24.2 percent versus minus 2.1 percent on placebo — the highest magnitude ever reported in a Phase 2 obesity study. Every participant at the top dose lost at least 5 percent of starting weight; about 63 percent lost 25 percent or more, and 26 percent lost 30 percent or more. These are Phase 2 numbers in a selected trial population, and the definitive Phase 3 outcome data (TRIUMPH-1) are not yet published. Real-world magnitude will depend on dose tolerated, titration success, adherence, and the diet-and-training foundation built around the medication.

When will retatrutide be FDA-approved?

Eli Lilly has publicly guided Phase 3 TRIUMPH-1 obesity primary readout for the late 2026 window, with regulatory submissions expected to follow. Under a standard 10-month FDA review, the earliest realistic obesity-indication approval is late 2027 or 2028. Semaglutide moved from Phase 3 STEP primary readouts (2018 to 2020) to Wegovy approval in June 2021, and tirzepatide moved from SURMOUNT-1 (April 2022) to Zepbound approval in November 2023, so an 18 to 36 month runway from readout to pharmacy shelf is the historical pattern. No specific date is publicly committed, and any safety signal in Phase 3 could extend the timeline.

Is retatrutide safe?

The Phase 2 safety picture was broadly consistent with the incretin class — dose-dependent nausea, vomiting, diarrhea, and constipation, most mild-to-moderate and cluster-managed with slower titration. There was a small resting heart-rate rise (about 4 bpm at the 12 mg dose) that resolved with continued exposure, and no hepatic-fat safety signal. Because the glucagon arm is the novel mechanism, long-term hepatic, glycemic, and cardiovascular safety are what Phase 3 is designed to characterize. Class-wide GLP-1 warnings (pancreatitis, gallbladder events, medullary thyroid cancer contraindication for personal or family history and MEN2) will almost certainly carry to any approved label. Long-term human safety data beyond the Phase 2 window are not yet available.

Can I buy retatrutide right now?

No — not legally, not from any legitimate pharmacy, and not as the Lilly molecule from the trial. Retatrutide is not FDA-approved and Eli Lilly does not sell it to patients or through any pharmacy channel. Products marketed as 'retatrutide' by telehealth clinics, research-peptide vendors, or gray-market compounding pharmacies are unregulated peptides that have not been tested for identity, purity, dose accuracy, or sterility. Compounding pharmacies cannot legally compound retatrutide under 503A rules because retatrutide has never been on the FDA drug-shortage list and is not an approved active ingredient. Waiting for the FDA-approved product is the only safe route.

Will retatrutide be covered by insurance?

There is no way to know until it is approved and priced. If retatrutide follows the semaglutide and tirzepatide precedent, expect list prices in the same 1,000 to 1,400 dollars per month band, with manufacturer direct-to-consumer programs (analogous to LillyDirect for Zepbound) available at reduced cash prices. Commercial insurance coverage will hinge on whether individual plans include obesity-drug benefits — many still exclude the class. Medicare Part D currently excludes anti-obesity medications by statute, though pathways open when a specific drug carries a cardiovascular or sleep-apnea indication (Wegovy under SELECT, Zepbound under SURMOUNT-OSA). Any cost or coverage number quoted specifically for retatrutide today is speculation.

Is retatrutide sold online real retatrutide?

Almost certainly not the Lilly investigational product. The compound Eli Lilly is testing in the TRIUMPH program is proprietary; Lilly does not sell or license the active pharmaceutical ingredient to third parties. Vials sold online as 'retatrutide' by research-peptide and telehealth-adjacent vendors typically arrive as lyophilized peptide of unverified identity, purity, and concentration, often manufactured overseas outside FDA cGMP oversight. FDA analyses of compounded and gray-market GLP-1 products (Rubino 2023 JAMA on compounded semaglutide) have documented mislabeled potency, subpotent product, wrong salt forms, and bacterial contamination. Injecting these products is not the same intervention that produced the 24 percent Phase 2 signal — and it is not safe.

Retatrutide for Weight Loss: What the Triple-Agonist Actually Is, and Why You Can’t Buy It Yet

Retatrutide is an investigational triple-agonist weight-loss drug from Eli Lilly. It has not been FDA-approved as of publication, is not commercially available at any legitimate pharmacy, and any online product sold today as “retatrutide” is unregulated compounded peptide — often not what the label claims, sometimes contaminated, and always outside the safety-monitoring system that governs approved drugs. This page explains what retatrutide is, what Phase 2 and Phase 3 evidence shows, when a legitimate market launch may occur, and how it fits into the 2026 weight-loss-medication landscape. For the compounded-peptide safety picture in more depth, see compounded semaglutide and tirzepatide safety.

What retatrutide is (LY3437943)

Retatrutide, development code LY3437943, is a single synthetic peptide engineered to bind and activate three receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. In pharmacology terms it is a triple agonist or tri-agonist. It is delivered as a once-weekly subcutaneous injection, similar in cadence and route to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

The distinction from the other two drug families is where the mechanism adds a lever. Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide adds glucagon receptor activation on top of both. GLP-1 and GIP activation produce the appetite suppression, delayed gastric emptying, improved insulin sensitivity, and central satiety signals familiar from the existing incretin drugs. The glucagon arm — traditionally thought of only as a fasting glucose-raising hormone — adds two levers the incretin-only drugs do not: an increase in resting energy expenditure and mobilization of hepatic (liver) fat.

The mechanistic foundation for retatrutide was described in Coskun 2022 (Cell Metabolism), which established that carefully balanced tri-receptor engagement could produce additive appetite and metabolic effects without the destabilizing hyperglycemia that pure glucagon agonism might cause. For the broader picture of what the incretin class does and how single-, dual-, and triple-receptor drugs compare, see the GLP-1 weight loss overview.

How it differs from tirzepatide and semaglutide

The 2026 incretin landscape is easier to follow with the four leading drugs side by side. The comparison below is between separate trials with different populations and durations — no head-to-head retatrutide-vs-tirzepatide-vs-CagriSema trial exists yet — but it establishes the mechanistic hierarchy the field is organized around.

Two takeaways matter. First, adding receptors adds weight-loss magnitude — but the increment is not linear, and the trade-off is that each new receptor extends the safety story that Phase 3 has to characterize. Second, the head-to-head questions everyone wants answered (retatrutide vs tirzepatide, retatrutide vs CagriSema) do not have direct trial answers yet. Cross-trial comparisons between separate studies always overstate the certainty of the difference. For the on-label version of the semaglutide-vs-tirzepatide question that most patients actually face today, see semaglutide vs tirzepatide; for the within-Lilly pipeline-vs-approved head-to-head — mechanism, magnitude, side-effect trade-off, and the “should I wait” decision — see retatrutide vs tirzepatide.

What the Phase 2 trial actually showed

The pivotal published dataset is Jastreboff 2023 (NEJM 389:514–526), the retatrutide Phase 2 obesity trial. It enrolled 338 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus at least one weight-related comorbidity, and randomized them across five dose arms (1, 4, 8, 12 mg weekly subcutaneous) plus placebo, with dose escalation to target over the first several weeks. Follow-up was 48 weeks.

The headline numbers at the 12 mg dose:

• Mean weight change: minus 24.2 percent vs minus 2.1 percent on placebo — the largest Phase 2 magnitude ever reported in obesity pharmacology
• 100 percent of participants at 12 mg lost at least 5 percent of starting weight
• 63 percent lost at least 25 percent
• 26 percent lost at least 30 percent

Every dose arm produced a statistically significant weight-loss signal versus placebo, and the dose-response was steep and monotonic — higher doses produced meaningfully more weight loss, without a plateau at 8 mg. That dose-response steepness is why the 12 mg dose is the reasonable Phase 3 anchor.

Safety in Phase 2 was, in the aggregate, consistent with the incretin class expectations:

• Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) dose-dependent, mostly mild-to-moderate, and manageable through slower titration
• Small resting heart-rate rise of roughly 4 beats per minute at 12 mg — attributable to the glucagon-agonism arm — which resolved with continued exposure
• No hepatic-fat safety signal (an active question given the glucagon arm); if anything, liver-fat markers improved
• Small dose-dependent glucose fluctuations, but no clinically meaningful hyperglycemia
• No unexpected class-outside safety findings

A separate Rosenstock 2023 (The Lancet) Phase 2 trial in adults with type 2 diabetes reported clinically meaningful A1c reduction and weight loss. Phase 2 evidence for retatrutide is unusually strong for a Phase 2 program, and it is why the Phase 3 TRIUMPH set is the most-watched obesity-drug program of the decade.

The Phase 3 TRIUMPH program

Eli Lilly’s Phase 3 development for retatrutide is organized as a five-trial TRIUMPH program covering the major populations and comorbidities the drug will eventually be prescribed for. Enrollment began in 2023 and 2024. All primary endpoint readouts are pending as of publication.

The Phase 3 obesity arm (TRIUMPH-1) is the pivotal read that will anchor an FDA obesity-indication filing. TRIUMPH-2 (obesity + T2D) will typically feed a companion diabetes indication — semaglutide (Ozempic before Wegovy) and tirzepatide (Mounjaro before Zepbound) both followed that sequence. TRIUMPH-3 is the cardiovascular outcomes trial that would potentially unlock a Medicare Part D pathway and payer coverage in ways the obesity-only indication does not. TRIUMPH-4 is the pediatric arm; if positive, it would open adolescent use in the 12 to 17 range, similar to the STEP-TEENS (Weghuber 2022) pathway that expanded Wegovy to adolescents. TRIUMPH-5 (obesity + knee osteoarthritis) mirrors the growing evidence base for weight-loss pharmacology as a joint-disease intervention.

For the broader pipeline map covering retatrutide alongside orforglipron, CagriSema, survodutide, MariTide, and mazdutide — the first dual GLP-1 / glucagon receptor agonist to reach approval anywhere in the world (China NMPA, June 2025) — see next generation weight loss drugs.

Realistic FDA-approval timeline

The honest read is that no specific approval date is publicly committed, and any date-certain answer you see online is speculation. What we do know:

• Eli Lilly has guided TRIUMPH-1 primary readout for the late 2026 window
• Regulatory submissions for a positive readout typically follow within roughly 6 months
• FDA priority review is 6 months and standard review is 10 months from submission acceptance
• Manufacturing scale-up and payer formulary decisions add additional months after approval

Applying the historical analogs: semaglutide had Phase 3 STEP primary readouts in 2018 to 2020 and Wegovy was approved in June 2021 — about 12 to 30 months from readout to shelf, depending on which STEP trial anchored the filing. Tirzepatide had the SURMOUNT-1 primary readout in April 2022 and Zepbound was approved in November 2023 — about 19 months from readout to shelf. Applied to retatrutide, that suggests the earliest realistic FDA-approval decision for the obesity indication is late 2027 or 2028, with pharmacy availability shortly after.

The T2D indication (TRIUMPH-2) may reach the FDA first depending on trial sequencing, and could reach patients under a diabetes-brand pathway before the obesity brand exists. The MACE outcome trial (TRIUMPH-3) will be the slowest to read out but the most consequential for insurance coverage. These are ranges, not dates. Any safety signal in Phase 3 could extend the timeline by 12 to 24 months or shift the label.

How retatrutide might be priced and covered

Nothing about retatrutide’s US pricing has been announced because the drug is not yet approved. What can be said honestly is that the current second-generation drugs anchor the reference range:

• Wegovy (semaglutide 2.4 mg): roughly 1,349 dollars per month US list, roughly 349 to 499 dollars per month through the LillyDirect / NovoCare direct-to-consumer cash channel
• Zepbound (tirzepatide): roughly 1,059 dollars per month US list, roughly 349 to 499 dollars per month through LillyDirect single-dose vials

If retatrutide is priced in the same band on a class-anchored basis, expect a list price in the roughly 1,000 to 1,400 dollars per month range with a direct-manufacturer cash channel available at a discount. This is analogy, not disclosure.

Insurance coverage will follow the same fault lines the current class faces. Commercial-plan coverage for obesity drugs remains inconsistent — many employer plans exclude the anti-obesity class entirely, and prior-authorization with BMI criteria plus documented lifestyle-attempt evidence is common. Medicare Part D excludes anti-obesity drugs by statute (Section 1860D-2(e)(2)(A) of the Social Security Act), a rule that has not been broadly repealed as of 2026. The current pathway around that exclusion opens only when a specific drug carries a non-obesity indication with a cardiovascular or comparable benefit — Wegovy under SELECT (Lincoff 2023 NEJM) and Zepbound under SURMOUNT-OSA (Malhotra 2024 NEJM) both use that door. Retatrutide’s TRIUMPH-3 cardiovascular outcomes trial is the equivalent lever for a future Medicare pathway. For the full 2026 pricing table and coverage landscape across the class, see GLP-1 cost and insurance.

What “retatrutide” sold online today actually is

This is the hardest-hitting section of the article, and the most important. Compounded and gray-market vials labeled “retatrutide” appeared on telehealth clinics, research-peptide vendors, and offshore online pharmacies in the wake of the Jastreboff 2023 NEJM Phase 2 publication. They are typically priced 200 to 500 dollars per month. They are not the Lilly investigational product.

Four hard facts govern the compounded-retatrutide picture:

1. Eli Lilly is the only manufacturer of the retatrutide molecule used in the TRIUMPH trials. Lilly does not sell the active pharmaceutical ingredient (API) to any pharmacy, compounder, or third party. Any vial sold as “retatrutide” is a peptide synthesized elsewhere, of unverified identity.
2. Compounding pharmacies cannot legally compound retatrutide under 503A rules. The 503A/503B compounding pathway requires either an FDA drug-shortage listing (which briefly covered compounded semaglutide and tirzepatide in 2022 to 2024 during genuine shortage) or an approved active ingredient. Retatrutide has never been on the shortage list — it has never been approved — so the legal basis for compounding it does not exist.
3. No regulator tests these products for potency, sterility, or identity. Rubino 2023 (JAMA) analyzed compounded semaglutide samples during the 2023 shortage window and documented mislabeled potency, subpotent product, and wrong salt forms. Retatrutide compounding, being fully outside any legal pathway, has even less oversight.
4. The compounded-semaglutide-and-tirzepatide precedent does not transfer. During the 2022 to 2024 shortage, some compounded semaglutide and tirzepatide had a limited legal pathway. That pathway closed when the FDA declared the shortages resolved (semaglutide October 2023; tirzepatide December 2024). Retatrutide never had that pathway.

The practical translation: any dose of any vial labeled “retatrutide” purchased from a non-Lilly source is an injection of unknown material at an unknown dose. It is not the intervention that produced the 24.2 percent Phase 2 signal. It is outside every safety-monitoring system that governs approved drugs. Adverse events do not funnel to FDA MedWatch in a way that produces safety signal detection. Read compounded semaglutide and tirzepatide safety and weight loss drug safety for the full picture on gray-market injectable safety.

The correct answer for a reader who wants retatrutide is to wait for the FDA-approved product.

Who retatrutide might be for (once approved)

The Phase 3 TRIUMPH program is designed to establish the likely indication landscape. Extrapolating from the trial populations and the current semaglutide / tirzepatide labels gives a reasonable projection of who a future retatrutide prescription would fit — and the class-wide contraindications that will almost certainly appear on the eventual label.

Retatrutide will almost certainly carry the class-wide GLP-1 boxed warning for medullary thyroid cancer risk (based on rodent thyroid C-cell tumor data extrapolated across the incretin class), a pancreatitis warning, and gallbladder-disease monitoring language. Combination with insulin or sulfonylureas will raise hypoglycemia risk and typically require dose adjustment of those medications. For the tirzepatide-specific version of the same eligibility framework, which is the closest currently-approved analog, see tirzepatide for weight loss; for the semaglutide framework, see semaglutide for weight loss.

Side effects and safety signals to watch

The Phase 2 safety profile establishes what the class-anchored expectations are, and it also flags the areas Phase 3 was designed to characterize. Read these as trial-level findings that Phase 3 may confirm, refine, or overturn.

• Gastrointestinal (nausea, vomiting, diarrhea, constipation) — dose-dependent, mostly mild-to-moderate, cluster around dose escalations, manageable with slower titration. Rate is higher at the 8 and 12 mg doses than at 1 or 4 mg.
• Small resting heart-rate increase (roughly 4 bpm at 12 mg) attributable to the glucagon-agonism arm; resolved with continued exposure in Phase 2. Phase 3 cardiovascular outcomes will determine whether this is a durable or clinically meaningful signal.
• Gallbladder events — a class effect across GLP-1 drugs (Sodhi 2023 JAMA), and expected to carry to retatrutide.
• Injection-site reactions — expected at the same rate as tirzepatide and semaglutide.
• Rare but serious: acute pancreatitis (class-wide), hypersensitivity reactions, Stevens-Johnson syndrome (rare across the class).

The most novel safety questions for retatrutide, beyond the shared class profile, are:

• Long-term hepatic safety — the glucagon arm can theoretically affect liver enzymes and lipid handling. Phase 2 did not show a hepatic safety signal; Phase 3 in a larger and longer-followed population is the definitive read.
• Long-term glycemic safety — the glucagon arm is glucose-raising in isolation, but the balance with GLP-1 and GIP appears net-favorable in Phase 2. Long-duration Phase 3 data in T2D populations (TRIUMPH-2) is the test.
• Muscle preservation — as with all high-magnitude weight-loss interventions, roughly 20 to 30 percent of the weight lost with incretin-class drugs is lean mass (Sattar 2022; Wilding 2021 STEP-1 body-composition sub-analysis). Higher-magnitude drugs put more absolute muscle at risk. See preserve muscle during weight loss and strength training for weight loss for the protein and resistance-training scaffolding that offsets it.

Retatrutide vs the other 2026-pipeline drugs

Retatrutide is not the only next-generation drug in Phase 3. The pipeline includes several distinct mechanisms and dosing formats, each with a Phase 2 or Phase 3 topline that reshapes the future prescribing landscape. Numbers are the highest topline weight-loss magnitude published to date.

Retatrutide sits at the top of the weight-loss-magnitude column but not at the top of the “reaches patients first” column — orforglipron, Lilly’s own once-daily oral non-peptide GLP-1, is on a 2026–2027 FDA-review timeline with a Wegovy-tier weight-loss magnitude in a pill and no fridge, needle, or fasting-window requirement, which puts it ahead of retatrutide on the shelf-date column. CagriSema’s Phase 3 topline was slightly below Novo Nordisk’s pre-trial expectation (about 25 percent) but still substantial, and the full REDEFINE trial table and 2026 compounded-safety picture are covered in the CagriSema for weight loss pillar. MariTide’s monthly cadence and reported persistence-after-stopping signal are the most conceptually distinctive items in the pipeline. Read the next generation weight loss drugs pillar for the full comparison and each drug’s mechanism.

What to do if you’re waiting for retatrutide

The honest recommendation for most adults with obesity and a candidate diagnosis for pharmacotherapy in 2026 is: do not wait. The realistic pharmacy-shelf date for retatrutide is 18 to 36 months after the TRIUMPH-1 readout, and untreated obesity accumulates cardiovascular, metabolic, joint, and psychological burden every year of that wait. A four-step practical protocol:

1. Consider currently approved second-generation options with your clinician. Tirzepatide (Zepbound) is the closest currently-approved analog to retatrutide in mechanism and magnitude — it produces roughly 20.9 percent mean weight loss at 72 weeks in eligible adults (SURMOUNT-1). Starting today is not a lock-in; switching to retatrutide at approval is straightforward once it exists. Semaglutide (Wegovy) is the other on-label option, with 14.9 percent weight loss and a cardiovascular-risk-reduction indication under SELECT.
2. Build the lifestyle scaffolding now. The muscle preservation and metabolic health you carry into a medication window meaningfully shape outcomes. A protein floor of roughly 1.6 g/kg body weight per day, resistance training two to three times per week (strength training for weight loss), and 7-plus hours of sleep is the baseline the medication builds on. See preserve muscle during weight loss for the muscle-retention protocol that applies to every drug in this class.
3. Get baseline labs and BMI/waist documented before the market launch. A recent lipid panel, HbA1c, liver enzymes, thyroid panel, BMI, and waist circumference create the insurance-approval-ready record most prior-authorization systems want. Your primary-care visit or an obesity-medicine consult is the right venue.
4. Do NOT buy compounded retatrutide from any online source. The 2026 gray market for peptides labeled “retatrutide” is unsafe, illegal in the sense that it operates outside 503A/503B compounding rules, and — most importantly — does not deliver the drug the Phase 2 trial studied. Wait for the FDA-approved product. See compounded semaglutide and tirzepatide safety for the full 2026 enforcement landscape.

For the full 2026 prescription-weight-loss-medication hub and the honest comparison of every currently-approved option, see prescription weight loss medications.